KDventures to Write Down Umecrine Stake to Zero After Trial Miss
KDventures will write down its Umecrine Cognition holding from SEK 226.4 million to zero after golexanolone failed to show significant benefit versus placebo in a PBC Phase 1b/2a Part B trial. The move reduces NAV by SEK 226.4 million, or about SEK 0.30 per share.